Along with the February traffic numbers, Delta Air Lines (NYSE:DAL) reported a key stat returned to flat after an extended period of negative prints. The stock, though, shook off the improving trend with an initial decline due to the weak market.
Apple (NASDAQ:AAPL) is expected to launch a trio of new iPhones in September. These new phones are expected to incorporate significant internal enhancements compared to the models that launched last fall, including support for super-fast gigabit LTE download speeds.
In a federal filing Monday morning, Harley-Davidson Inc. (NYSE: HOG) said that the tariff on motorcycles exported from the United States to Europe will rise from a current 6% to 31% and add an average of $2,200 to the price of a Harley in Europe. The tariff was implemented in retaliation for U.S. President Trump’s 25% tariff on European steel imports.
Nektar Therapeutics (NASDAQ:NKTR) is an intriguing commercial-stage biotech company that’s just reported positive late-stage trial results for its pain-busting drug NKTR-181. However, shares have jumped on the news, and the company’s market cap has swollen to more than $3 billion. Is there more running room left for its investors?
SAN FRANCISCO If it’s a high-paid job, chances are you won’t find a woman in it.
That’s the conclusion of a LinkedIn analysis, prepared forEqual Pay Day on Tuesday, of how women fared in the top 100 highest-paying jobs in the U.S. On average, women make up less than 30% of employees in each role. Among thehighest-paid roles, only threeof them employ more women than men all....More>>>
Following billionaire investor Warren Buffett into stocks he owns has often been a profitable strategy over the past few decades. But reversing the orderbuying a stock before Buffett buys itcan potentially be even more rewarding.
Quiz: How Well Do You Really Know Warren Buffett?
With that in mind, we went prospecting for companies that Berkshire Hathaway (BRK-B, $137), Buffetts holding....More>>>
The management of regulatory affairs essentially contributes to the overall success of new drug development – both at early pre-marketing stages and at all times post-marketing. This means that a biotech or pharma company’s regulatory affairs personnel will be heavily involved in all stages of new drug development both prior to and after an FDA approval.
Encana (NYSE:ECA) (TSE:ECA) had its target price raised by Morgan Stanley from $16.00 to $20.00 in a research report report published on Wednesday morning. Morgan Stanley currently has a buy rating on the oil and gas company’s stock.
Equities research analysts predict that LivaNova PLC (NASDAQ:LIVN) will announce sales of $277.80 million for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for LivaNova’s earnings, with estimates ranging from $277.40 million to $278.20 millio
Zacks Investment Research upgraded shares of Idacorp (NYSE:IDA) from a hold rating to a buy rating in a report issued on Thursday morning. They currently have $101.00 target price on the coal producer’s stock.
According to Zacks, “In a year's time shares of IDACORP
Zacks Investment Research upgraded shares of Idacorp (NYSE:IDA) from a hold rating to a buy rating in a report released on Thursday. The firm currently has $99.00 price target on the coal producer’s stock.
According to Zacks, “In a year's time shares of IDACORP ha